• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    3/5/24 12:33:15 PM ET
    $APGE
    $BYSI
    $CMAX
    $EKSO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APGE alert in real time by email

    Gainers

    • Sunshine Biopharma (NASDAQ:SBFM) stock rose 142.3% to $0.11 during Tuesday's regular session. The company's market cap stands at $5.9 million.
    • Ocean Biomedical (NASDAQ:OCEA) shares rose 54.65% to $6.31. The company's market cap stands at $215.0 million.
    • Apogee Therapeutics (NASDAQ:APGE) shares rose 50.83% to $62.96. The market value of their outstanding shares is at $3.0 billion.
    • BeyondSpring (NASDAQ:BYSI) shares rose 46.34% to $2.4. The market value of their outstanding shares is at $93.6 million.
    • CareMax (NASDAQ:CMAX) shares increased by 33.85% to $10.32. The company's market cap stands at $38.6 million.
    • Protagenic Therapeutics (NASDAQ:PTIX) shares increased by 31.79% to $1.32. The company's market cap stands at $5.8 million.

    Losers

    • Quoin Pharmaceuticals (NASDAQ:QNRX) shares fell 45.9% to $1.57 during Tuesday's regular session. The market value of their outstanding shares is at $1.5 million.
    • Ekso Bionics Holdings (NASDAQ:EKSO) stock declined by 24.71% to $1.58. The company's market cap stands at $28.1 million. The company's, Q4 earnings came out yesterday.
    • Lipella Pharmaceuticals (NASDAQ:LIPO) stock declined by 22.34% to $0.8. The company's market cap stands at $4.9 million.
    • Kineta (NASDAQ:KA) stock decreased by 22.28% to $0.79. The market value of their outstanding shares is at $8.1 million.
    • Eyenovia (NASDAQ:EYEN) stock declined by 22.15% to $1.77. The market value of their outstanding shares is at $78.3 million.
    • Semler Scientific (NASDAQ:SMLR) shares declined by 18.3% to $39.91. The market value of their outstanding shares is at $274.3 million. The company's, Q4 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APGE
    $BYSI
    $CMAX
    $EKSO

    CompanyDatePrice TargetRatingAnalyst
    Apogee Therapeutics Inc.
    $APGE
    1/22/2026$83.00Outperform → Sector Perform
    RBC Capital Mkts
    Apogee Therapeutics Inc.
    $APGE
    1/7/2026Peer Perform
    Wolfe Research
    Apogee Therapeutics Inc.
    $APGE
    12/17/2025$95.00Overweight
    Stephens
    Apogee Therapeutics Inc.
    $APGE
    12/10/2025$103.00Buy
    Deutsche Bank
    Apogee Therapeutics Inc.
    $APGE
    11/3/2025$109.00Buy
    Craig Hallum
    Apogee Therapeutics Inc.
    $APGE
    10/21/2025$105.00Outperform
    Mizuho
    Apogee Therapeutics Inc.
    $APGE
    9/25/2025$60.00Outperform
    RBC Capital Mkts
    Semler Scientific Inc.
    $SMLR
    7/28/2025Overweight
    Cantor Fitzgerald
    More analyst ratings

    $APGE
    $BYSI
    $CMAX
    $EKSO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Dambkowski Carl exercised 4,125 shares at a strike of $22.86 and sold $390,825 worth of shares (5,500 units at $71.06), decreasing direct ownership by 0.65% to 209,773 units (SEC Form 4)

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    3/6/26 8:00:10 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Henderson Jane sold $140,431 worth of shares (2,000 units at $70.22), decreasing direct ownership by 1% to 181,371 units (SEC Form 4)

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    3/4/26 8:00:25 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Asher Daniel bought $191,162 worth of shares (15,540 units at $12.30) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/20/26 4:57:37 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $APGE
    $BYSI
    $CMAX
    $EKSO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for MYDCOMBI issued to EYENOVIA INC.

    Submission status for EYENOVIA INC.'s drug MYDCOMBI (ORIG-1) with active ingredient TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE has changed to 'Approval' on 05/05/2023. Application Category: NDA, Application Number: 215352, Application Classification: Type 5 - New Formulation or New Manufacturer

    5/8/23 1:05:04 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGE
    $BYSI
    $CMAX
    $EKSO
    SEC Filings

    View All

    Sunshine Biopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Sunshine Biopharma Inc. (0001402328) (Filer)

    3/9/26 4:05:28 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Protagenic Therapeutics Inc.

    10-Q - Protagenic Therapeutics, Inc.\new (0001022899) (Filer)

    3/9/26 7:46:11 AM ET
    $PTIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Apogee Therapeutics Inc.

    SCHEDULE 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)

    3/6/26 12:57:46 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    $BYSI
    $CMAX
    $EKSO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Asher Daniel bought $191,162 worth of shares (15,540 units at $12.30) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/20/26 4:57:37 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Large owner Asher Daniel bought $11,520 worth of shares (1,200 units at $9.60) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/19/26 4:03:47 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Large owner Asher Daniel bought $970,069 worth of shares (102,029 units at $9.51) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/17/26 3:42:24 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $APGE
    $BYSI
    $CMAX
    $EKSO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

    — Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — — QRX003 lotion (4%) currently being evaluated in two late-stage whole-body clinical trials for treatment of Netherton Syndrome — — Fast Track Designation follows Pediatric Rare Disease and Orphan Drug Designation previously granted by the FDA and Orphan Drug Designation granted by the European Medicines Agency for QRX003 in Netherton Syndrome — ASHBURN, Va., March 11, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on d

    3/11/26 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results

    Zumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway:- APEX Phase 2 Part A 52-week data expected this month- APEX Phase 2 Part B 16-week data expected in Q2 2026- Phase 3 trial initiation in AD anticipated in 2H 2026- Successful expansion of zumilokibart beyond AD demonstrated in asthma Phase 1b trial; details on asthma and eosinophilic esophagitis (EoE) trials expected later this year Phase 1b head-to-head trial of APG279 (zumilokibart + APG990) vs. DUPIXENT underway, with interim AD data anticipated in 2H 2026 Strong total cash position of $902.9 million with runway into 2H 2028 supports advancement toward potential laun

    3/2/26 7:00:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome

    ASHBURN, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- In recognition of Rare Disease Day® 2026, Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) today highlighted the continued growth of its NETHERTON NOW awareness campaign, which seeks to amplify the voices of patients, caregivers and clinicians impacted by Netherton Syndrome, a rare genetic disease with no approved treatment or cure. Rare Disease Day, observed annually on the last day of February during Rare Disease Month, was established in 2008 by EURORDIS to raise awareness of rare conditions and the profound challenges faced by those living with them. While each rare disease affects a relatively small population, collectively rare diseases impact

    2/26/26 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $APGE
    $BYSI
    $CMAX
    $EKSO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Apogee Therapeutics downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Apogee Therapeutics from Outperform to Sector Perform and set a new price target of $83.00

    1/22/26 8:24:52 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wolfe Research initiated coverage on Apogee Therapeutics

    Wolfe Research initiated coverage of Apogee Therapeutics with a rating of Peer Perform

    1/7/26 9:08:42 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stephens initiated coverage on Apogee Therapeutics with a new price target

    Stephens initiated coverage of Apogee Therapeutics with a rating of Overweight and set a new price target of $95.00

    12/17/25 9:12:28 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    $BYSI
    $CMAX
    $EKSO
    Leadership Updates

    Live Leadership Updates

    View All

    Strive Announces the Completion of Semler Scientific Acquisition

    DALLAS, TX, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Strive, Inc. (NASDAQ:ASST) ("Strive") today announced the successful completion of the previously announced acquisition of Semler Scientific. Strive now holds approximately 12,797.9 bitcoin, becoming the #11 largest public corporate holder of bitcoin globally. Strive also announces the appointment of Avik Roy as Chief Strategy Officer of Strive. Mr. Roy's initial focus will be on Strive's intentions to monetize the operating business from the Semler Scientific subsidiary by expanding its mandate in early disease detection products.  Mr. Roy began his career in science at MIT and trained as a physician at Yale Medical School before joining Ba

    1/16/26 8:40:00 AM ET
    $ASST
    $SMLR
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Strive, Inc. (Nasdaq: ASST) and Semler Scientific, Inc. (Nasdaq: SMLR) Announce Bitcoin Treasury Merger in All-Stock Transaction

    DALLAS, TX and CAMPBELL, CA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Strive, Inc. ("Strive") entered into a definitive agreement to acquire Semler Scientific, Inc. ("Semler Scientific") in an all-stock transaction. In addition, Strive announced the purchase of 5,816 Bitcoin to its corporate treasury at an average price of $116,047 per Bitcoin, for a total purchase price of $675,000,000, inclusive of fees and expenses, bringing Strive's total Bitcoin holdings to 5,886. Transaction details: Deal represents an approximately 210% premium, equivalent to approximately $90.52 per share, based on the trading price of Semler Scientific common stock and Strive Class A common stock as of the market clos

    9/22/25 8:15:00 AM ET
    $ASST
    $SMLR
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

    ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) ("Quoin" or the "Company"), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its new Chief Financial Officer as the Company advances its lead product candidate, QRX003, through pivotal clinical studies and prepares for potential commercialization. Quoin has appointed Sally Lawlor, BCL, FCA, as its new Chief Financial Officer, effective immediately. Ms. Lawlor is an accomplished finance executive with over 20 years of experience in financial leadership roles in public and private companies as well as a Big Four accounting fir

    8/18/25 8:30:00 AM ET
    $QNRX
    Medical/Dental Instruments
    Health Care

    $APGE
    $BYSI
    $CMAX
    $EKSO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Semler Scientific Inc.

    SC 13D/A - Semler Scientific, Inc. (0001554859) (Subject)

    12/12/24 4:16:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Eyenovia Inc.

    SC 13D/A - EYENOVIA, INC. (0001682639) (Subject)

    12/4/24 4:12:20 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Semler Scientific Inc.

    SC 13G - Semler Scientific, Inc. (0001554859) (Subject)

    11/26/24 12:09:40 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $APGE
    $BYSI
    $CMAX
    $EKSO
    Financials

    Live finance-specific insights

    View All

    Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

    Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of FeNO through 32 weeks for patients with available follow up - Results reinforce continued development in asthma testing every 3- or 6-month dosing Successful expansion of zumilokibart beyond dermatology confirms its pipeline-in-a-product potential across I&I indications Zumilokibart in atopic dermatitis (AD) advancing in Phase 2 APEX trials with goal of Phase 3 initiation by end of 2026:- Part A maintenance (52-week) data readout expected in Q1 2026 with potential to establish best-in-class e

    1/6/26 6:00:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026

    SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report interim results from its Phase 1b trial of APG777 in patients with mild-to-moderate asthma on Tuesday, January 6, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET to discuss the results. Webcast DetailsApogee Therapeutics' live webcast of the APG777 Phase 1b asthma interim results will begin on Tuesday, January 6th at 8:00 a.m. ET. Th

    1/5/26 4:01:00 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Semler Scientific® to Release Third Quarter 2025 Financial Results

    CAMPBELL, Calif., Oct. 28, 2025 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ:SMLR), the second U.S. public company to adopt Bitcoin as its primary treasury reserve asset and a leader in medical devices and software to combat chronic diseases, today announced that due to its pending transaction with Strive, Inc., the company will not be hosting a conference call or providing an accompanying earnings presentation in conjunction with its third quarter 2025 financial results. Semler Scientific intends to file its Quarterly Report on Form 10-Q for the period ended September 30,

    10/28/25 5:05:00 PM ET
    $SMLR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care